/**
 * Static SEO article: NF1 pharmacology pipeline, Koselugo (selumetinib) regulatory milestones,
 * and commercial/access research instrumentation — pairs with pillar `/nf1-pharma-market-research`.
 */
import type { BlogPost } from '@/types/blog';

export const NF1_KOSELUGO_BLOG_SLUG = 'nf1-koselugo-selumetinib-pharma-market-research';

export const NF1_KOSELUGO_COVER_IMAGE = '/images/blog/nf1-koselugo-selumetinib-cover.jpg';

export const NF1_KOSELUGO_META_TITLE = 'NF1 & Koselugo (Selumetinib): Pharma Research & MAP | BioNixus';

export const NF1_KOSELUGO_DISPLAY_TITLE =
  'NF1 & Koselugo (Selumetinib): Market Access Signals, Competitive Intelligence, and HCP Insight Design';

export const NF1_KOSELUGO_META_DESCRIPTION =
  'Neurofibromatosis type 1 (NF1) landscape, MEK inhibition with Koselugo (selumetinib)—approved by FDA (Apr 2020 pediatrics ≥2 y; label expanded to pediatric ≥1 y Sept 2025; adults Nov 2025)—and how pharma teams localize evidence for payers & specialists. Links to BioNixus NF1 pharma research pillar.';

export const NF1_KOSELUGO_OG_DESCRIPTION = NF1_KOSELUGO_META_DESCRIPTION;

export const NF1_KOSELUGO_PUBLISHED_ISO = '2026-05-26T09:00:00.000Z';
export const NF1_KOSELUGO_UPDATED_ISO = NF1_KOSELUGO_PUBLISHED_ISO;

/** Rich entities for NF1-focused Article / BlogPosting `mentions`. */
export const NF1_KOSELUGO_SCHEMA_MENTIONS: ReadonlyArray<Record<string, unknown>> = [
  {
    '@type': 'MedicalCondition',
    name: 'Neurofibromatosis type 1',
    alternateName: ['NF1', 'von Recklinghausen disease'],
    url: 'https://www.ncbi.nlm.nih.gov/books/NBK1109/',
  },
  {
    '@type': 'Drug',
    name: 'Selumetinib',
    alternateName: ['Koselugo'],
  },
];

export const NF1_KOSELUGO_TAGS = [
  'Neurofibromatosis type 1',
  'NF1',
  'Koselugo',
  'Selumetinib',
  'Rare disease pharma research',
  'Healthcare market research',
  'MEA',
] as const;

export const NF1_KOSELUGO_SCHEMA_FAQ: { question: string; answer: string }[] = [
  {
    question: 'What is neurofibromatosis type 1?',
    answer:
      'NF1 is an autosomal dominant tumour‑predisposition syndrome caused by heterozygous pathogenic NF1 mutations. Clinical hallmarks include café‑au‑lait macules, axillary inguinal freckling, Lisch iris nodules, skeletal dysplasia risks, optic pathway gliomas, cognitive/school‑age learning differences for some families, and plexiform neurofibromas (PNs)—diffuse peripheral nerve sheath tumours that cause disfigurement, pain, airway compromise, and functional deficits when untreated.',
  },
  {
    question: 'What is Koselugo (selumetinib)?',
    answer:
      'Koselugo is an oral selective MEK1/MEK2 inhibitor that targets hyperactive signalling downstream of neurofibromin loss in NF1-associated tumours; it reduces proliferation of tumour cells reliant on aberrant RAS/MAPK activity. Regulatory labelling evolves—always consult current FDA/EMA SmPC prescribing information for dosing, formulations (capsules, oral suspension granules where applicable), and monitoring (e.g., cardiac echocardiography, dermatologic toxicity, ophthalmology). Development has been pursued under an AstraZeneca–MSD (Merck & Co.) collaboration.',
  },
  {
    question: 'What major FDA approvals exist for Koselugo in NF1?',
    answer:
      'FDA approved selumetinib capsules (KOSELUGO) on 10 April 2020 for pediatric patients ≥2 years with symptomatic, inoperable PNs attributable to NF1 (first FDA‑approved systemic therapy targeting this phenotype). Subsequent US label updates expanded pediatric eligibility downward and, on 19 November 2025, added adult patients ≥18 years with symptomatic inoperable PNs—underscoring a multigenerational treatable cohort and new launch economics for rare‑disease oncology franchises.',
  },
  {
    question: 'Which other therapeutic options do NF1 patients still use?',
    answer:
      'High‑burden lesions may undergo partial debulking or laser debulking when feasible; malignant peripheral nerve sheath tumours require oncology pathways. MEK inhibition does not negate surveillance MRI cadence per specialty consensus. Early‑stage clinical assets (novel MEK combos, scaffold protein modulators, others) imply future share‑of‑therapy scenarios—premium market intelligence quantifies neurologist/oncologist/center switching assumptions.',
  },
  {
    question: 'What European regulatory context applies?',
    answer:
      'The European Medicines Agency maintains a centrally authorised dossier for Koselugo covering paediatric cohorts beginning at preschool ages (see EPAR dosing tables). Adults with symptomatic inoperable PNs received broader Commission marketing authorisations in autumn 2025, harmonising continental access with renewed pharmacovigilance obligations and national pricing dossiers.',
  },
  {
    question: 'How should pharmaceutical teams localize NF1 forecasting?',
    answer:
      'Triangulate genomics‑aware prevalence, neurology/oncology/paediatric tertiary centre catchment overlaps, multidisciplinary tumour board adjudication timelines, caregiver administration burden with oral dosing, cardiologist co‑management for MEK inhibition, imaging capacity, tender vs retail financing in Gulf states, SFDA dossier parity versus EU/US SmPC deltas, Arabic informed‑consent translation quality, social listening on advocacy channels, analogues from other RAS‑pathway rare diseases—and stress‑test analogue adoption curves versus registry‑based incident PN counts.',
  },
  {
    question: 'Which BioNixus deliverables differentiate NF1 research?',
    answer:
      'Incidence‑aware clinician sampling matrices, neurologist/oncologist/paediatric tumour board ethnography modules, payer committee simulation boards in Saudi/UAE analogue markets, analogue pricing corridors for specialised oral kinase inhibitors in rare disease tenders, multilingual digital diaries capturing caregiver dosing friction, longitudinal chart‑audit analogues respecting privacy, qualitative ATU after educational symposia, competitive battlecards benchmarking pipeline MEK combos, linkage to GCC hospital procurement analytics (BioNixus consumption intelligence)—all governed under GDPR‑aligned methodologies described on the methodology page.',
  },
  {
    question: 'Where can I find the authoritative clinical detail page?',
    answer:
      'Use the complementary open‑access pillar on NF1 pharma market intelligence with therapy tables linking regulatory milestones, formulary analogue analogues for MEK inhibition, stakeholder maps, FAQs, BioNixus capability matrix—and deep internal links toward therapy directories, oncology research hub, qualitative/quant guides, GCC pharma consumption report, Saudi/UAE pharma company dossiers.',
  },
];

export const NF1_KOSELUGO_EXECUTIVE_SUMMARY_HTML = `<p><strong>Three commercial signals pharma strategists weigh for NF1 in 2026</strong></p>
<ul>
<li><strong>Expanded treatable adulthood</strong> — US approval (Nov 2025) stretches addressable PN patients beyond pediatric centres into adult neurologist/oncologist clinics; forecast models must refactor centre mix and persistence assumptions.</li>
<li><strong>Parallel EU harmonisation</strong> — Autumn 2025 European Commission uptake for adults creates near‑simultaneous transatlantic brand planning—localized pharmacovigilance and SmPC divergence still matter.</li>
<li><strong>Portfolio crowding readiness</strong> — Additional MEK / combination entrants in oncology pipelines raise future share erosion scenarios; competitive intelligence trackers should embed neurology tumour board analogues—not only sarcoma comps.</li>
<li><strong>Operational note</strong> — Pair qualitative depth with reproducible incidence‑aware quantitative cores using the methodologies on our <a href="/methodology">healthcare research methodology hub</a> and comparative tender intelligence on the <a href="/gcc-pharma-market-report-2026">GCC pharmaceutical market snapshot 2026</a>.</li>
</ul>`;

export const NF1_KOSELUGO_TABLE_OF_CONTENTS = [
  { heading: 'Executive snapshot & cross-links', anchor: 'snapshot' },
  { heading: 'Disease fundamentals', anchor: 'disease-context' },
  { heading: 'Pharmacologic rationale — MEK inhibition', anchor: 'mek-story' },
  { heading: 'Koselugo regulatory chronology', anchor: 'regulatory-milestones' },
  { heading: 'Competitive positioning & analogue analogies', anchor: 'commercialization' },
  { heading: 'BioNixus research architecture for NF1 franchises', anchor: 'bionixus' },
];

export const NF1_KOSELUGO_BODY_HTML = `<p>This brief is informational market research commentary—not medical guidance. NF1 franchises now operate under a bifurcated evidence ecosystem: longstanding supportive/surgical workflows versus targeted MEK inhibition that materially shrinks tumour volume for many paediatric and now adult plexiform neurofibroma patients carrying symptomatic lesions. Regulatory milestones for <strong>Koselugo<sup>®</sup> (selumetinib)</strong> underpin both US reimbursement dossiers and ex‑US HTA dossiers—but cross‑national labelling deltas, dosing formats, ophthalmology/cardiac monitoring nuances, centre capacity, caregiver adherence, advocacy expectations, tender analogues from other oral kinase inhibitors, and pipeline MEK combination assets all shape analogue forecast confidence.</p>

<p>For the structured numerical tables, formulary analogue analogues, BioNixus capability matrix (quant/qual payer workshops, tumour board analogue boards), and FAQs, see our dedicated pillar <a href="/nf1-pharma-market-research">NF1 pharma market research &amp; Koselugo competitive intelligence landing page</a>. Also cross‑read the oncology therapy hub <a href="/healthcare-market-research/therapy/oncology">healthcare oncology market research</a>, rare‑disease‑adjacent indications on <a href="/pharmaceutical-therapy-areas">pharmaceutical therapy areas directory</a>, and analogous rare‑tumor coverage on <a href="/desmoid-tumor-pharma-market-research">desmoid tumour pharma intelligence</a> with its commentary article <a href="/blog/desmoid-tumors-nirogacestat-pharma-market-access">desmoid tumours — Ogsiveo (nirogacestat) pharma market intelligence</a>.</p>

<h2 id="snapshot">Executive snapshot</h2>
<ul>
<li><strong>Prevalence context</strong> — NF1 live‑birth prevalence is often cited ~1 : 3 000, implying material diagnosed cohorts in national systems when accounting for ascertainment.</li>
<li><strong>Unmet surgical burden</strong> — Symptomatic, inoperable PNs disproportionately steer healthcare utilisation toward imaging cadence, pain management, plastic surgery liaison, airway/GI compression escalations—and now chronic oral targeted therapy stewardship.</li>
<li><strong>Launch economics analogue</strong> — Treat‑to‑MRI response metrics, tumour volume reduction adjudication laboratories, speciality pharmacy dispensing, cardiologist co‑management, and MEK inhibitor class safety communications resemble other oral targeted rare‑tumor arcs—commercial teams import analogue analogies cautiously rather than mechanically.</li>
<li><strong>Internal research stack anchors</strong> — <a href="/services/market-access">market access dossier rehearsals</a>, <a href="/services/quantitative-research">quantitative HCP &amp; centre surveys</a>, <a href="/services/qualitative-research">qualitative tumour board analogue boards</a>, <a href="/services/competitive-intelligence">competitive intelligence trackers</a>, <a href="/real-world-evidence-gcc">RWE ingestion playbooks GCC</a>, <a href="/methodology">operational QA methodology disclosure</a>.</li>
</ul>

<h2 id="disease-context">NF1 phenotype relevant to pharma segmentation</h2>
<p>Commercial segmentation must respect clinical heterogeneity: families with predominant cutaneous manifestations differ from airway‑centric or paraspinal PNs imposing orthopaedic/neurosurgical escalation. Pharmacotherapy candidates cluster around imaging‑measurable symptomatic lesions versus watch‑and‑wait phenotypes—affecting dosing persistence analogues alongside adverse‑event mediated discontinuation corridors.</p>

<h2 id="mek-story">Pharmacologic rationale</h2>
<p>Functional loss of neurofibromin disinhibits RAS→RAF→MEK→ERK signalling; MEK inhibition places a pharmacodynamic gate downstream blocking excessive ERK phosphorylation cascades operative in tumour cells driving PN proliferation. Combination strategies (pipeline or investigator‑initiated trials) revisit resistance mechanisms and adaptive MAPK signalling feedback—forecast models should embed hypothetical future share‑erosion deltas.</p>

<h2 id="regulatory-milestones">Koselugo regulatory milestones (selected)</h2>
<table>
  <thead>
    <tr><th>Jurisdiction</th><th>Milestone emphasis</th><th>Commercial implication</th></tr>
  </thead>
  <tbody>
    <tr><td>United States FDA</td><td>First approval Apr 2020 paediatrics ≥2 y symptomatic inoperable PNs; iterative label expansions through 2025 including paediatrics ≥1 y and adults with symptomatic inoperable PNs (Nov 2025).</td><td>Widened prescriber base &amp; multi‑lifecycle pricing analogues akin other chronic oral rare tumour therapies.</td></tr>
    <tr><td>EU / European Commission</td><td>Centralised paediatric authorisation preceded adult extension (Commission decision Oct 2025 cluster).</td><td>Parallel EU–US tenders &amp; early access dossier harmonisation feasibility—still subject national pricing corridors.</td></tr>
    <tr><td>Other geography analogues</td><td>SFDA NHIC alignment in Gulf states &amp; UK NHS ICS frameworks—localized tender intelligence required.</td><td>Use BioNixus Saudi/UAE dossier rehearsals &amp; tender analytics cross‑linked below.</td></tr>
  </tbody>
</table>

<h2 id="commercialization">Competitive layering & analogue analogies</h2>
<ul>
<li><strong>Plexiform vs cutaneous tumour accounting</strong> — Forecast models distinguishing imaging‑eligible PN burden vs benign cutaneous nodular manifestations avoid inflating reachable patient equivalents.</li>
<li><strong>Pipeline crowding sentinel</strong> — Additional MEK or combo assets shift share under varying response depth / AE trade‑off assumptions—simulate ATU deltas post congress data drops.</li>
<li><strong>Procurement parallels</strong> — Gulf tender analogues resemble other chronic oral anticancer kinase inhibitors reimbursed after hospital speciality pharmacy adjudication loops—see <a href="/saudi-payer-market-access-research">Saudi payer market access research</a>.</li>
</ul>

<h2 id="bionixus">How BioNixus operationalizes NF1 insight programs</h2>
<ul>
<li><strong>Incidence‑aware sampling</strong> — Align physician completes with tertiary NF referral centre density—not generic neurologist quotas.</li>
<li><strong>Multilingual qualitative depth</strong> — Arabic caregiver / adolescent transition modules with ethical IRB overlays when patient voice permitted.</li>
<li><strong>Access simulation boards</strong> — Pairs economists with payer archetypes mirroring centralized Gulf tenders &amp; UK ICS ICER‑style critiques.</li>
<li><strong>Competitive overlays</strong> — Integrate pipeline trackers with congress intelligence &amp; share‑of‑voice social listening—not silo charts.</li>
<li><strong>Linkage to pillar analytics</strong> — Hospital consumption benchmarking from <a href="/gcc-pharma-market-report-2026">GCC pharmaceutical market report 2026</a> complements primary NF1 clinician research.</li>
</ul>

<p><strong>Tender &amp; company landscape cross‑reads:</strong>
<a href="/pharmaceutical-companies-saudi-arabia">Saudi pharma company directory</a> · 
<a href="/pharmaceutical-companies-uae">UAE pharma intelligence</a> · 
<a href="/pharmaceutical-companies-egypt">Egypt pharma dossier snapshots</a> · 
<a href="/budget-impact-model-saudi-arabia">budget impact modelling Saudi footprint</a> · 
<a href="/kol-mapping-saudi-arabia-oncology">oncology KOL mapping Saudi playbook</a> · 
<a href="/quantitative-healthcare-market-research">quantitative healthcare market research playbook</a> · 
<a href="/patient-support-program-research-gcc">patient support program GCC research</a> · 
<a href="/market-research-home">insights data hub homepage</a> · 
<a href="/blog/gcc-pharmacoeconomics">GCC pharmacoeconomics dossier rehearsal article</a> · 
<a href="/contact">contact BioNixus multidisciplinary research cell</a>.
</p>

<p class="text-sm opacity-70">Medico‑legal: Regulatory facts synthesised May 2026; corroborate with FDA &amp; EMA EPAR originals before dossier filings. Imaging / persistence analogues illustrative—modelling bespoke to geography.</p>`;

export const NF1_STATIC_BLOG_SCHEMA_ITEM_LIST = {
  name: 'NF1 franchise planning modules',
  items: [
    {
      name: 'PN eligibility analogue modelling',
      description:
        'MRI‑eligible symptomatic tumour burden segmentation vs watchful waiting—aligns dosing persistence & AE discontinuations.',
    },
    {
      name: 'Adolescent‑to‑adult transition analogue',
      description:
        'Captures dosing ownership shift from caregiver‑led paediatrics to self‑managed adult neurologist corridors post Nov 2025 adult approval.',
    },
    {
      name: 'Centre capacity & echocardiography throughput',
      description:
        'Operational bottleneck intelligence for cardiologist echo cadence mandated under MEK label monitoring—forecast adoption ceilings.',
    },
    {
      name: 'Combination pipeline sentinel',
      description:
        'Scenario trees stress‑testing pipeline MEK doublets / scaffold protein inhibition share erosion vs monotherapy inertia.',
    },
    {
      name: 'Regional tender analogue overlays',
      description:
        'GCC centrals + EU ICS pricing narratives harmonized with clinician ATU vignettes—not spreadsheet tourism.',
    },
  ],
};

/** Skeleton enabling SSR + Sanity absence fallback. */
export const NF1_KOSELUGO_HARDCODED_POST: BlogPost = {
  id: 'hardcoded-blog-nf1-koselugo',
  slug: NF1_KOSELUGO_BLOG_SLUG,
  title: NF1_KOSELUGO_DISPLAY_TITLE,
  excerpt:
    'Rare NF1 tumour burden, MEK inhibitor Koselugo (selumetinib)—FDA approvals for paediatrics (Apr 2020; expanded ≥1 y Sept 2025) and adults (Nov 2025)—EU adult expansion Autumn 2025. Commercial research design for specialists, carers, tenders, analogue analogies.',
  date: '26 May 2026',
  category: 'Rare Disease',
  country: 'Global',
  language: 'en',
  readingTime: 22,
  tags: [...NF1_KOSELUGO_TAGS],
  coverImage: NF1_KOSELUGO_COVER_IMAGE,
  ogImage: NF1_KOSELUGO_COVER_IMAGE,
  ogTitle: NF1_KOSELUGO_META_TITLE,
  ogDescription: NF1_KOSELUGO_OG_DESCRIPTION,
  seoMetaTitle: NF1_KOSELUGO_META_TITLE,
  seoMetaDescription: NF1_KOSELUGO_META_DESCRIPTION,
  seoCanonicalUrl: `https://www.bionixus.com/blog/${NF1_KOSELUGO_BLOG_SLUG}`,
  authorName: 'Mohammad Ashour',
  authorTitle: 'Research Lead, BioNixus Healthcare Market Research',
  authorLinkedIn: 'https://www.linkedin.com/in/mohammad-alsaadany',
  publishedAtIso: NF1_KOSELUGO_PUBLISHED_ISO,
  updatedAtIso: NF1_KOSELUGO_UPDATED_ISO,
  tableOfContents: NF1_KOSELUGO_TABLE_OF_CONTENTS.map(({ heading, anchor }) => ({ heading, anchor })),
  faq: NF1_KOSELUGO_SCHEMA_FAQ,
  ctaSection: {
    title: 'Design incidence-aware NF1 market intelligence',
    description:
      'Blend MEK analogue analogies, tumour board behavioural modules, multilingual caregiver depth, payer simulation boards — orchestrated by GDPR-aligned field governance.',
    buttonText: 'Book an NF1 research consult',
    buttonUrl: '/contact',
  },
  body: '.',
};
